In 2011, Martin Shkreli—then 29 years old and a rather outspoken manager of the hedge fund MSMB Capital Management—attracted some acclaim when he started his own biotech company, Retrophin, and began pursuing therapies for rare diseases. He served at the helm of Retrophin until last fall, when the company ousted him, later alleging that he improperly passed off legal settlements with MSMB investors as consulting agreements. Now Retrophin is taking the dispute with the controversial entrepreneur a step further.
Retrophin filed a federal lawsuit against Shkreli on Monday in New York alleging that he created the biotech and took it public solely to provide stock to MSMB investors when the hedge fund became insolvent. The suit seeks more than $65 million in damages and a requirement that Shkreli disgorge all the compensation he received from Retrophin during the time he acted as a “faithless servant” to it, as the claim reads. Turing Pharmaceuticals, another biotech startup that Shkreli founded this past February, is not named in the suit.